UnknownNot Applicable

Controlled Trial to Demonstrate a Reduction in the Number of Oliguria Events in Patients Being Managed in a Critical Care Unit, Following Cardiac Surgery, When a Novel Oliguria Prediction Tool (STABILITY UO) is Used to Identify Patients at Risk, Compared to Standard of Care.

United Kingdom362 participantsStarted 2022-05

Plain-language summary

Acute kidney injury (AKI) is experienced by 12% of patients following surgery and in up to 50% of patients following cardiac surgery. It is associated with an increased risk of death and prolonged stay in critical care after surgery. In addition to the patient impact, AKI costs the NHS alone between £434m and £620m per year. One way that AKI is diagnosed is by looking at a patient's urine output and checking how much is produced over time. If this value is too low for a patient, they are diagnosed with oliguria. Too many of these oliguria events leads to a diagnosis of AKI. The product to be tested (Stability UO) aims to reduce the number of patients who suffer three or more oliguria events after surgery by processing the data entered by the care team and providing the care team with additional information about the patient's risk of oliguria over the next six hours. Patients over 18 who present at Manchester University NHS Foundation Trust for non-emergency cardiac surgery will be screened and asked to consent to be randomised as part of the trial. Patients undergoing certain operations and those with unsuitable medical history (e.g. patients being treated for dialysis) will not be invited to participate. The randomisation will determine if their care team has access to the Stability UO software after surgery. While the care team looks after the patients in the cardiothoracic critical care unit (CTCCU) after surgery, they will enter that the patient's weight and amount of urine passed each hour into the software and review the output. The primary questions the study will answer is if there is a difference between number of oliguria events between the two groups of patients. The study is funded by the device manufacturer: Rinicare Ltd.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient is willing and able to give informed consent for participation in the study, including being able to receive study materials at least 24 hours prior to their planned operation, * Patient is Male or Female, aged 18 years or above, * Patient is due to undergo elective or urgent cardiac surgery, and who is expected to be managed on the CTCCU postoperatively, * In the Investigator's opinion, able and willing to comply with all study requirements. Exclusion Criteria: * Patients undergoing emergency surgery (i.e surgery that has to take place in the next available theatre even if this is out of standard operating hours) * Patients having ventricular assist device implantation, * Patients receiving a heart transplant, * Patients who would be unable to be treated by standard of care CTCCU therapies and practices, * Patients who are receiving pre or intra-operative dialysis or haemofiltration. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

What they're measuring

Absolute Risk Reduction (ARR) of patients experiencing ≥3 oliguria events.

Timeframe: post cardiac surgery CTCCU stay (average 2-5 days with some staying more than 3 months)

Trial details

NCT IDNCT05001503

SponsorRinicare Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-05

Contact for this trial

Eric D Carlson, MRes

+44 (0)1615 37 59 29 eric@rinicare.com